Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JaNEO: Neoadjuvant Vinflunine and Cisplatin in Muscle-Invasive Bladder Cancer
NCT02845050Phase 2Withdrawn
- Start
- Jul 2016
- Primary completion
- Jul 2017
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vinflunine in muscle-invasive bladder cancer (MIBC). Planned start Jul 2016; status: withdrawn.
02
Drugs
vinflunine
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT02845050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02845050.